Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK and PD of BI 653048 with LPS Challenge in Healthy Males
NCT02224105Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2010
- Primary completion
- May 2010
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of BI 653048 in rheumatoid arthritis (RA) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of subjects with adverse events up to 37 days, Number of subjects with clinically significant findings in vital signs and 5 more. Started Mar 2010; status: completed.
02
Drugs
BI 653048
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02224105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02224105.